The Impact of Osteoporotic Fractures on Patients with Rheumatoid Arthritis in Work Disability
DOI:
https://doi.org/10.3889/oamjms.2022.9769Keywords:
Osteoporosis, Rheumatoid arthritis, Work disabilityAbstract
Osteoporosis is the one of most common chronic metabolic bone disease, which is characterized by increased bone fragility, which is highly affected by age and menopause.1 According to the International Osteoporosis Foundation, one in three women over the age of 50 experience at least once in a lifetime a fracture as a result of osteoporosis, which on another hand is a cause for work disability.2,3
Objective: The purpose of the study is to evaluate the economic and social impact of work disability, caused by fractures as a result of osteoporosis on patients with RA.
Material and Methods: The study included 50 patients, diagnosed with RA and osteoporosis, which have had at least one fracture during their course of disease. The data were obtained in the Regional Hospital of Elbasan and the main focus was the duration of work disability.
Results: The research concluded that approximately 20% of the patients required a long term disability benefit after suffering a fracture. Furthermore, the majority of the patients were reluctant to go back to work after suffering the consequences of the fracture, mainly due to pain and inability to properly move.
Conclusion: Fractures due to osteoporosis on patients with RA have an increasing impact in work disability and life quality. The majority of the patients taken into research have benefited from work disability policies, whether short or long-term.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-95. https://doi.org/10.1001/jama.285.6.785 PMid:11176917 DOI: https://doi.org/10.1001/jama.285.6.785
Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520-6. https://doi.org/10.1002/jbmr.2269 PMid:24771492 DOI: https://doi.org/10.1002/jbmr.2269
Tuzun S, Eskiyurt N, Akarirmak U, Saridogan M, Senocak M, Johansson H, et al. Incidence of hip fracture and prevalence of osteoporosis in Turkey: The FRACTURK study. Osteoporos Int. 2012;23(3):949-55. https://doi.org/10.1007/s00198-011-1655-5 PMid:21594756 DOI: https://doi.org/10.1007/s00198-011-1655-5
Australian Institute of Health and Welfare. Snapshot of Arthritis in Australia 2010. Canberra: Australian Institute of Health and Welfare; 2010.
Itoh Y. Metalloproteinases: Potential therapeutic targets for rheumatoid arthritis. Endocr Metab Immune Disord Drug Targets. 2015;15(3):216-22. https://doi.org/10.2174/1871530315666150316122335 PMid:25772173 DOI: https://doi.org/10.2174/1871530315666150316122335
Wright NC, Lisse JR, Walitt BT, Eaton CB, Chen Z, Women’s Health Initiative Investigators. Arthritis increases the risk for fractures results from the women’s health initiative. J Rheumatol. 2011;38(8):1680-8. https://doi.org/10.3899/jrheum.101196 PMid:21572148 DOI: https://doi.org/10.3899/jrheum.101196
Lee SG, Park YE, Park SH, Kim TK, Choi HJ, Lee SJ, et al. Increased frequency of osteoporosis and BMD below the expected range for age among South Korean women with rheumatoid arthritis. Int J Rheum Dis. 2012;15(3):289-96. https://doi.org/10.1111/j.1756-185X.2012.01729.x PMid:22709491 DOI: https://doi.org/10.1111/j.1756-185X.2012.01729.x
Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine. 2010;77(3):201-5. https://doi.org/10.1016/j.jbspin.2010.03.002 PMid:20444632 DOI: https://doi.org/10.1016/j.jbspin.2010.03.002
Prall WC, Haasters F, Heggebo J, Polzer H, Schwarz C, Gassner C, et al. Mesenchymal stem cells from osteoporotic patients feature impaired signal transduction but sustained osteoinduction in response to BMP-2 stimulation. Biochem Biophys Res Commun. 2013;440(4):617-22. https://doi.org/10.1016/j.bbrc.2013.09.114 PMid:24099772 DOI: https://doi.org/10.1016/j.bbrc.2013.09.114
Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts. Biochem Biophys Res Commun. 2005;329(1):177-81. https://doi.org/10.1016/j.bbrc.2005.01.117 PMid:15721290 DOI: https://doi.org/10.1016/j.bbrc.2005.01.117
Wang FS, Lin CL, Chen YJ, Wang CJ, Yang KD, Huang YT, et al. Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology. 2005;146(5):2415-23. https://doi.org/10.1210/en.2004-1050 PMid:15677765 DOI: https://doi.org/10.1210/en.2004-1050
van den Bergh JP, van Geel TA, Geusens PP. Osteoporosis, frailty and fracture: Implications for case finding and therapy. Nat Rev Rheumatol. 2012;8(3):163-72. https://doi.org/10.1038/nrrheum.2011.217 PMid:22249162 DOI: https://doi.org/10.1038/nrrheum.2011.217
Kaz Kaz H, Johnson D, Kerry S, Chinappen U, Tweed K, Patel S. Fall-related risk factors and osteoporosis in women with rheumatoid arthritis. Rheumatology (Oxford). 2004;43(10):1267-71. https://doi.org/10.1093/rheumatology/keh304 PMid:15252210 DOI: https://doi.org/10.1093/rheumatology/keh304
Yamazaki T, Yamori M, Yamamoto K, Saito K, Asai K, Sumi E, et al. Risk of osteomyelitis of the jaw induced by oral bisphosphonates in patients taking medications for osteoporosis: A hospital-based cohort study in Japan. Bone. 2012;51(5):882- 7. https://doi.org/10.1016/j.bone.2012.08.115 PMid:22917933 DOI: https://doi.org/10.1016/j.bone.2012.08.115
Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, et al. Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(4):R154. https://doi.org/10.1186/ar3107 PMid:20682035 DOI: https://doi.org/10.1186/ar3107
Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: Effects of disease, social, and work factors. Ann Intern Med. 1980;93(4):551-6. https://doi.org/10.7326/0003-4819-93-4-551 PMid:7436187 DOI: https://doi.org/10.7326/0003-4819-93-4-551
Sokka T. Work disability in early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S71-4. PMid:14969054
Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: Five-year experience from the FIN-RACo trial. Arthritis Rheum. 2005;52(1):36-41. https://doi.org/10.1002/art.20716 PMid:15641055 DOI: https://doi.org/10.1002/art.20716
Verstappen SM, Jacobs JW, Hyrich KL. Effect of anti-tumor necrosis factor on work disability. J Rheumatol. 2007;34(11):2126-8. PMid:17985411
Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 2003;48(11):3046-54. https://doi.org/10.1002/art.11285 PMid:14613265 DOI: https://doi.org/10.1002/art.11285
Chung CP, Sokka T, Arbogast P, Pincus T. Work disability in early rheumatoid arthritis: Higher rates but better clinical status in Finland compared with the US. Ann Rheum Dis. 2006;65(12):1653-7. https://doi.org/10.1136/ard.2005.048439 PMid:16740683 DOI: https://doi.org/10.1136/ard.2005.048439
De Buck PD, Schoones JW, Allaire SH, Vliet-Vlieland TP. Vocational rehabilitation in patients with chronic rheumatic diseases. A systematic literature review. Semin Arthritis Rheum. 2002;32(3):196-203. https://doi.org/10.1053/sarh.2002.34609 PMid:12528084 DOI: https://doi.org/10.1053/sarh.2002.34609
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2022 Evis Skuqi, Irena Kola, Sh. M. Sander Kola (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
